Op2Lysis has been nominated for the Prix GALIEN USA 2023, in the Best StartUp category. The Prix Galien recognises outstanding achievements in improving human health and well-being around the world through the development of drugs, medical devices and other innovative approaches to better manage disease. The press release is available below:
The World Intracranial Hemorrhage Conference (WICH) meets every two years and brings together neurologists, neurosurgeons, researchers and clinicians from all fields, healthcare providers, students and community members from around the world to provide a unique opportunity to exchange ideas and share research and clinical innovations in the field of intracranial haemorrhage. The WICH 2023 conference […]
Op2Lysis was awarded a Deeptech Development Grant (ADD) to manufacture the clinical batch of OptPA, the active substance in O2L-001, for phase 1/2 in patients suffering from cerebral haemorrhage. The press release:
In 2022, Op2Lysis has taken on a new dimension with the support of the EIC Accelerator in Europe, Bpifrance in France and Win4Company in Belgium. The following sections describe the company’s progress on corporate, technical and regulatory fronts. We would also like to take this opportunity to wish a happy new year 2023 to all […]